evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

336 questions · 354 findings · 32 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 71 · 20.1%GRADE not reported 33 · 9.3%Very low 70 · 19.8%Low 82 · 23.2%Moderate 75 · 21.2%High 23 · 6.5%

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Clinically relevant non‐major bleeding ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Escalated BEACOPP vs chemotherapy including ABVD

Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL

Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).

1 finding from 1 review

Escalated BEACOPP vs chemotherapy including ABVD

Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL

Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).

1 finding from 1 review

Escalated BEACOPP vs chemotherapy including ABVD

Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL

Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).

1 finding from 1 review

Escalated BEACOPP vs chemotherapy including ABVD

Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL

Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).

1 finding from 1 review

Escalated BEACOPP vs chemotherapy including ABVD

Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL

It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).

1 finding from 1 review

Fewer vs more courses of chemotherapy (with or without radiotherapy

Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)

Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).

1 finding from 1 review

Fewer vs more courses of chemotherapy (with or without radiotherapy

Death · Patients with untreated Hodgkin lymphoma (early stages)

Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

1 finding from 1 review

Fewer vs more courses of chemotherapy (with or without radiotherapy

Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)

Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

1 finding from 1 review